electroCore (ECOR) Completes Acquisition of NeuroMetrix
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
May 2, 2025 8:00 AM EDTROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR, electroCore, or the Company) (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the Merger) with NeuroMetrix, Inc. (NeuroMetrix or NURO) (Nasdaq: NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions.
The acquisition of NeuroMetrixs Quell® Fibromyalgia Solution expands electroCores portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach particularly within the VA Hospital System and is expected to meaningfully increase its addressable market for the treatment of chronic pain and wellness conditions.
Dan Goldberger, CEO... More
